BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7948319)

  • 1. [Reduced ex vivo production of superoxide anion by polymorphonuclear leukocytes during therapy with omeprazole. A pharmacological effect?].
    Capodicasa E; Ciaccio V; Corazzi F; De Bellis F; Bucaneve G; Ficola F; Pelli MA
    Minerva Gastroenterol Dietol; 1994 Sep; 40(3):105-11. PubMed ID: 7948319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omeprazole: blocks gastric acid secretion completely.
    Drug Ther Bull; 1990 Jun; 28(13):49-52. PubMed ID: 2131211
    [No Abstract]   [Full Text] [Related]  

  • 5. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omeprazole: a comprehensive review.
    Massoomi F; Savage J; Destache CJ
    Pharmacotherapy; 1993; 13(1):46-59. PubMed ID: 8437967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemolytic anemia associated with the use of omeprazole.
    Marks DR; Joy JV; Bonheim NA
    Am J Gastroenterol; 1991 Feb; 86(2):217-8. PubMed ID: 1992636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lansoprazole versus omeprazole in the treatment of reflux esophagitis.
    Vcev A; Stimac D; Vceva A; Rubinić M; Ivandić A; Ivanis N; Horvat D; Volarić M; Karner I
    Acta Med Croatica; 1997; 51(3):171-4. PubMed ID: 9248117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment.
    Bardhan KD; Cherian P; Jones RB; Vaishnavi A; Manek S; Bishop A; Polak J; Brooks A; Morris P; Thompson M; D'Silva J; Parkin S; Patterson J; Gillon KR
    Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):515-9. PubMed ID: 9513825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of acid pump antagonists (reversible PPIs).
    Wurst W; Hartmann M
    Yale J Biol Med; 1996; 69(3):233-43. PubMed ID: 9165692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of omeprazole therapy on peptic disease and serum gastrin levels in hemodialysis patients. A preliminary study.
    Montemurro NE; Di Maggio A; Loperfido A; Franceschi M; Scatizzi A
    Clin Nephrol; 1993 Nov; 40(5):296-8. PubMed ID: 8281719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease.
    Richter JE; Sabesin SM; Kogut DG; Kerr RM; Wruble LD; Collen MJ
    Am J Gastroenterol; 1996 Sep; 91(9):1766-72. PubMed ID: 8792695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omeprazole and reflux oesophagitis.
    Kerr GD
    Aliment Pharmacol Ther; 1994 Apr; 8(2):263. PubMed ID: 8038359
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy, safety, and cost issues in managing patients with gastroesophageal reflux disease.
    Garnett WR
    Am J Hosp Pharm; 1993 Apr; 50(4 Suppl 1):S11-8. PubMed ID: 8097363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
    Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
    Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lansoprazol ++ : a new proton pump inhibitor].
    Baczek J; Laskowiec G
    Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy.
    Bohmer CJ; Niezen-de Boer MC; Klinkenberg-Knol EC; Tuynman HA; Voskuil JH; Devillé WL; Meuwissen SG
    Am J Gastroenterol; 1997 Sep; 92(9):1475-9. PubMed ID: 9317066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Omeprazole].
    Isal JP
    Gastroenterol Clin Biol; 1987 Nov; 11(11):768-80. PubMed ID: 3322924
    [No Abstract]   [Full Text] [Related]  

  • 20. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.
    Schenk BE; Kuipers EJ; Klinkenberg-Knol EC; Eskes SA; Meuwissen SG
    Am J Gastroenterol; 1999 Apr; 94(4):884-7. PubMed ID: 10201451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.